Hermetica Superfood Encyclopedia
The Short Answer
Chromium nicotinate glycinate delivers trivalent chromium (Cr(III)) chelated with nicotinic acid and glycine, acting as a cofactor in insulin signaling by increasing insulin receptor density, activating IR β-subunit phosphorylation, and promoting GLUT4 translocation via the PI3K/Akt pathway. Rat studies demonstrate 3–8 times greater tissue retention compared to chromium picolinate, and the chelate form reduces gastrointestinal irritation associated with inorganic chromium salts, with supplemental doses of 200–1000 µg elemental chromium daily used clinically.
CategoryMineral
GroupMineral
Evidence LevelPreliminary
Primary Keywordchromium nicotinate glycinate benefits
Chromium Nicotinate Glycinate — botanical close-up
Health Benefits
**Glucose Metabolism Support**
Cr(III) enhances insulin receptor kinase activity and promotes GLUT4 vesicle translocation to the cell membrane, increasing cellular glucose uptake and improving glycemic control in insulin-resistant states.
**Insulin Sensitivity Enhancement**
By upregulating insulin receptor density and activating the PI3K/Akt signaling cascade, chromium nicotinate glycinate amplifies the cell's response to circulating insulin, reducing the insulin load required for normal glucose clearance.
**Reduction of Oxidative Stress and Inflammation**
Animal studies with chromium niacinate have documented reductions in pro-inflammatory cytokines TNF-α and IL-6, as well as C-reactive protein (CRP) and markers of lipid peroxidation in diabetic models, suggesting anti-inflammatory ancillary effects.
**Improved Lipid Profile**
Preclinical data indicate that chromium niacinate supplementation reduces circulating triglycerides and LDL cholesterol while modestly supporting HDL levels, likely through AMPK activation and downstream effects on hepatic lipid synthesis.
**Superior Bioavailability Over Inorganic Forms**
The nicotinate and glycine ligands stabilize Cr(III) in the gastrointestinal environment, yielding 3–8 times higher tissue retention in rodent models compared to chromium chloride or picolinate, translating to effective elemental chromium delivery at lower doses.
**ER Stress Mitigation**
Chromium supplementation inhibits JNK-mediated serine phosphorylation of insulin receptor substrate-1 (IRS-1), alleviating endoplasmic reticulum stress that underlies peripheral insulin resistance in metabolic syndrome models.
**Support for Chromium Deficiency in Clinical Nutrition**
The chelate form is used in total parenteral nutrition solutions at approximately 0.018 mg/L to correct chromium deficiency in critically ill or surgically recovering patients, preventing glucose intolerance associated with depleted chromium status.
Origin & History
Natural habitat
Chromium nicotinate glycinate is a synthetic chelated mineral supplement developed in the late 20th century through laboratory synthesis, combining trivalent chromium (Cr(III)) with nicotinic acid (vitamin B3) and the amino acid glycine as stabilizing ligands. It has no geographic or botanical origin, as it is manufactured through controlled ionic chelation chemistry rather than derived from natural plant or mineral sources. The compound was formulated to address the poor bioavailability of inorganic chromium salts, leveraging organic ligands to improve gastrointestinal absorption and stability in both oral supplements and total parenteral nutrition (TPN) solutions.
“Chromium nicotinate glycinate has no history in traditional medicine systems such as Ayurveda, Traditional Chinese Medicine, or indigenous herbal practices, as it is an entirely synthetic compound developed through modern nutritional biochemistry in the latter half of the 20th century. The concept of chromium as a nutritionally essential trace element was established in the 1950s–1960s by researchers Klaus Schwarz and Walter Mertz, who identified the glucose tolerance factor (GTF) as a chromium-containing complex required for normal insulin function in rats. Commercial chelated chromium supplements, including nicotinate and glycinate forms, emerged as a market category in the 1980s–1990s following growing interest in insulin sensitizers and weight management aids, coinciding with rising rates of type 2 diabetes and metabolic syndrome in Western populations. The synthesis of chromium with nicotinic acid was partly motivated by the natural co-occurrence of chromium and niacin in brewer's yeast, a traditional dietary source that was historically associated with improved glucose tolerance in animal feeding studies.”Traditional Medicine
Scientific Research
The clinical evidence base for chromium nicotinate glycinate specifically is limited, with no large-scale randomized controlled trials (RCTs) identified using this exact chelate formulation in human populations; available human data are predominantly extrapolated from studies on related chromium forms such as chromium picolinate or polynicotinate. Animal studies using chromium niacinate in diabetic rat models have documented reductions in TNF-α, IL-6, CRP, and lipid abnormalities, and chromium(III) glycinate models have demonstrated hypoglycemic effects, though sample sizes and effect magnitudes are inconsistently reported across these preclinical publications. Pharmacokinetic rat studies provide the most specific comparative data, showing 3–8 times greater tissue retention for chromium nicotinate relative to picolinate over 6–12 hours, and human absorption estimates for chromium picolinate of approximately 2.8% (±1.14 SD) serve as the closest available reference point. The broader chromium supplementation literature, while including some human RCTs in type 2 diabetic populations, lacks sufficient specificity to the nicotinate glycinate chelate form to permit direct evidence translation, and this ingredient should be considered at the preclinical-to-preliminary human evidence stage.
Preparation & Dosage
Traditional preparation
**Oral Capsules/Tablets (Chelate Blend)**
200–1000 µg elemental chromium daily; the nicotinate glycinate chelate form is the standard commercial preparation for oral supplementation.
**Total Parenteral Nutrition (TPN) Solution**
018 mg/L intravenous chromium in TPN formulations for deficiency correction in clinical settings; administered under medical supervision
Approximately 0..
**Typical Maintenance Dose**
200–400 µg elemental chromium per day for general glucose metabolism support in adults, consistent with Adequate Intake (AI) estimates.
**Therapeutic Range**
400–1000 µg elemental chromium daily has been used in metabolic syndrome and insulin resistance research contexts, though doses above 1000 µg/day should be medically supervised.
**Timing**
Best taken with meals to align with postprandial insulin release and maximize synergistic effects on glucose uptake; splitting doses across two meals may improve tolerability.
**Standardization**
No universal standardization percentage is established for this chelate; products should declare elemental chromium content per serving to allow accurate dosing.
**Form Selection Note**
The nicotinate glycinate chelate is preferred over chromium chloride or oxide due to demonstrated superior bioavailability in preclinical models and reduced gastrointestinal irritation.
Nutritional Profile
Chromium nicotinate glycinate is a trace mineral chelate and does not contribute meaningful macronutrients (proteins, fats, or carbohydrates) to the diet at supplemental doses of 200–1000 µg elemental chromium daily. The elemental chromium content is the sole nutritionally active mineral component, provided as Cr(III) which is the biologically relevant, non-toxic oxidation state; the chelate structure (C₁₈H₁₂CrN₃O₆ for the trinicotinate core, molar mass 418.305 g/mol) incorporates three nicotinic acid (vitamin B3/niacin) units and glycine per chromium ion, contributing negligible niacin and glycine at typical supplemental doses. Bioavailability of Cr(III) from oral sources is low in absolute terms (0.5–10% GI absorption for chelated forms), but the nicotinate glycinate chelate demonstrates 3–8 times higher tissue retention in rodent models versus inorganic chromium salts or picolinate, with absorption enhanced by co-ingestion of vitamin C and niacin. The compound contributes no caloric value and is typically formulated without fillers that would alter its nutritional character.
How It Works
Mechanism of Action
Trivalent chromium (Cr(III)) functions as an essential cofactor in the glucose tolerance factor (GTF) complex, binding to chromodulin (low-molecular-weight chromium-binding substance, LMWCr) which potentiates insulin receptor tyrosine kinase activity upon insulin binding, leading to autophosphorylation of the IR β-subunit and downstream activation of phosphatidylinositol 3-kinase (PI3K) and protein kinase B (Akt). Akt phosphorylation drives translocation of glucose transporter-4 (GLUT4)-containing vesicles to the plasma membrane of skeletal muscle and adipose cells, substantially increasing glucose uptake independent of additional insulin stimulus. Concurrently, chromium activates AMP-activated protein kinase (AMPK), a cellular energy sensor that further promotes glucose uptake and fatty acid oxidation, while suppressing PTEN, a phosphatase that negatively regulates the PI3K/Akt axis. The glycine and nicotinate ligands in this chelate form serve primarily to protect Cr(III) from precipitation and oxidation in the gastrointestinal tract, ensuring intact delivery to intestinal mucosal transporters and maximizing elemental chromium absorption.
Clinical Evidence
Clinical investigation of chromium nicotinate glycinate as a distinct formulation remains sparse, with no published large-scale human RCTs reporting sample sizes, effect sizes, or confidence intervals specifically for this chelate. Broader chromium supplementation trials in type 2 diabetes have measured outcomes including fasting glucose, HbA1c, HOMA-IR, and lipid panels, with modest positive signals in some studies, but methodological heterogeneity and form variability limit cross-study conclusions. Preclinical diabetic rat studies using the niacinate component consistently show improvements in glycemic markers and inflammatory cytokines, lending biological plausibility to human application, but direct clinical translation requires formal validation. Given the absence of adequately powered, well-controlled human trials for this specific chelate, clinical confidence in efficacy claims beyond biological plausibility and general chromium deficiency correction remains low to moderate.
Safety & Interactions
Chromium nicotinate glycinate as a Cr(III) compound is considered generally safe at supplemental doses of 200–1000 µg elemental chromium daily, with no established tolerable upper intake level (UL) set by the U.S. Institute of Medicine due to insufficient evidence of adverse effects at typical intakes; the oral LD50 for Cr(III) compounds in rats exceeds 2000 mg/kg, providing a wide safety margin. The nicotinate component at pharmacological doses may potentiate the hepatotoxic effects of statins, augment vasodilatory effects of antihypertensives, or contribute to flushing reactions, though the niacin content in typical chromium supplement doses is far below the threshold for these effects. Individuals with renal impairment should use caution, as chromium accumulation may occur with reduced urinary clearance, and patients with known chromium sensitivity or dermatitis should avoid supplementation; Cr(VI) compounds are carcinogenic, but Cr(III) supplemental forms do not convert to Cr(VI) under normal physiological conditions. Pregnancy and lactation safety data are insufficient for doses above dietary levels; supplementation during pregnancy should be reserved for documented deficiency under medical supervision, and the compound is not recommended in children without clinical indication.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Chromium(III) nicotinate glycinate chelateChromium trinicotinate glycinateChelated chromium nicotinateCr(III) nicotinate glycinateChromium niacinate glycinate
Frequently Asked Questions
What is chromium nicotinate glycinate and how does it differ from chromium picolinate?
Chromium nicotinate glycinate is a chelated form of trivalent chromium (Cr(III)) bound with nicotinic acid (vitamin B3) and the amino acid glycine as stabilizing ligands, designed to improve gastrointestinal stability and bioavailability over inorganic chromium salts. Rodent pharmacokinetic studies show 3–8 times greater tissue retention for the nicotinate form compared to chromium picolinate over 6–12 hours post-dose, and the glycinate component further improves solubility and mucosal uptake via amino acid transport pathways. Chromium picolinate uses picolinic acid as its chelating ligand and has a more extensive human clinical trial database, whereas the nicotinate glycinate chelate is considered by some researchers to more closely mimic the naturally occurring glucose tolerance factor (GTF) chromium complex.
What is the recommended dose of chromium nicotinate glycinate for blood sugar support?
The standard supplemental dose for glucose metabolism support is 200–400 µg of elemental chromium daily for general use, taken with meals to align with postprandial insulin activity and maximize glucose uptake effects. In research contexts examining insulin resistance and metabolic syndrome, doses up to 1000 µg elemental chromium per day have been studied, though doses above this threshold should be used only under medical supervision due to insufficient long-term safety data. It is important to verify that supplement labels declare elemental chromium content rather than total chelate weight, as the molecular weight of the chelate complex is substantially higher than its elemental chromium content.
Is chromium nicotinate glycinate safe, and are there any drug interactions?
Chromium nicotinate glycinate as a Cr(III) compound is generally regarded as safe at typical supplemental doses of 200–1000 µg elemental chromium daily; no tolerable upper intake level has been formally established by U.S. regulatory bodies, and the oral LD50 for Cr(III) compounds in animal models exceeds 2000 mg/kg. Potential drug interactions include augmentation of insulin and oral hypoglycemic agents (requiring blood glucose monitoring to avoid hypoglycemia), and at high niacin doses the nicotinate component could theoretically interact with statins or antihypertensives, though the niacin load in standard chromium doses is pharmacologically negligible. Individuals with renal impairment should consult a physician before use due to potential chromium accumulation, and those taking diabetes medications should monitor glycemic response when initiating supplementation.
Does chromium nicotinate glycinate help with weight loss?
Chromium supplementation has been investigated for weight management based on its role in insulin sensitization and AMPK activation, which theoretically could reduce carbohydrate cravings, improve fat oxidation, and stabilize blood glucose fluctuations that drive appetite. However, clinical evidence specifically for chromium nicotinate glycinate in weight loss is absent, and the broader chromium supplement literature in human RCTs shows modest, often statistically non-significant effects on body weight or body composition. Any weight management benefit is likely indirect, mediated through improved glycemic control rather than direct lipolytic or appetite-suppressing mechanisms, and this compound should not be used as a primary weight loss intervention.
How does chromium nicotinate glycinate work at the molecular level to support insulin function?
After absorption, Cr(III) binds to chromodulin (low-molecular-weight chromium-binding substance), a chromium-activated protein that potentiates insulin receptor tyrosine kinase activity upon insulin binding, triggering autophosphorylation of the insulin receptor β-subunit. This activates the PI3K/Akt signaling cascade, leading to translocation of GLUT4 glucose transporter vesicles to the cell membrane of muscle and adipose tissue, increasing glucose uptake; simultaneously, chromium activates AMPK and suppresses PTEN, a phosphatase that otherwise inhibits insulin signaling. Additionally, chromium inhibits JNK-mediated serine phosphorylation of insulin receptor substrate-1 (IRS-1), which is a key mechanism of insulin resistance associated with inflammatory stress and endoplasmic reticulum dysfunction.
What foods contain chromium, and can I get enough chromium nicotinate glycinate from diet alone?
Chromium is naturally present in foods like broccoli, barley, oats, green beans, and nutritional yeast, though chromium nicotinate glycinate as a specific chelated form is only available through supplementation. Dietary chromium content varies widely depending on soil chromium levels and food processing methods, making it difficult to guarantee adequate intake from food alone. Most people consuming a balanced diet obtain 25–35 mcg of chromium daily, but those with insulin resistance or metabolic concerns may benefit from supplemental chromium nicotinate glycinate to reach therapeutic levels of 200–400 mcg per day.
Who benefits most from chromium nicotinate glycinate supplementation?
Individuals with insulin resistance, prediabetes, type 2 diabetes, and metabolic syndrome are primary candidates for chromium nicotinate glycinate, as research shows the greatest benefit in these populations where insulin sensitivity is compromised. Athletes and active individuals may also benefit, as chromium supports glucose metabolism during and after exercise; however, evidence in non-insulin-resistant populations is less robust. People with poor dietary chromium intake, including those on restrictive diets or consuming heavily processed foods, may experience improved glycemic control with supplementation.
How does the nicotinate and glycinate chelation in chromium nicotinate glycinate affect its effectiveness compared to other chromium forms?
The nicotinate (niacin) and glycinate amino acid ligands in this chelated form enhance absorption and cellular uptake by stabilizing chromium in the gastrointestinal tract and reducing competition for absorption with other minerals. This dual-chelation design may provide superior bioavailability compared to inorganic chromium salts and potentially better cellular utilization than single-ligand forms like chromium picolinate. The glycine component also supports insulin signaling independently, creating a synergistic effect that may contribute to improved insulin sensitivity beyond chromium's direct effects alone.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w chromium-nicotinate-glycinate curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
